These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 24498872

  • 1. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
    Mayer J, Arthur C, Delaunay J, Mazur G, Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, Kantarjian HM.
    BMC Cancer; 2014 Feb 06; 14():69. PubMed ID: 24498872
    [Abstract] [Full Text] [Related]

  • 2. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
    Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C.
    J Clin Oncol; 2012 Jul 20; 30(21):2670-7. PubMed ID: 22689805
    [Abstract] [Full Text] [Related]

  • 3. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ, Lee JH, Park HS, Lee JH, Seol M, Lee YS, Kang YA, Jeon M, Woo JM, Lee KH.
    Clin Lymphoma Myeloma Leuk; 2019 May 20; 19(5):290-299.e3. PubMed ID: 30879987
    [Abstract] [Full Text] [Related]

  • 4. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM.
    Clin Lymphoma Myeloma Leuk; 2014 Feb 20; 14(1):68-72. PubMed ID: 24220616
    [Abstract] [Full Text] [Related]

  • 5. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.
    BMC Cancer; 2017 Dec 14; 17(1):852. PubMed ID: 29241450
    [Abstract] [Full Text] [Related]

  • 6. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM.
    Cancer; 2017 Aug 15; 123(16):3050-3060. PubMed ID: 28387922
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.
    Leuk Res; 2019 Jan 15; 76():33-38. PubMed ID: 30529681
    [Abstract] [Full Text] [Related]

  • 8. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.
    N Engl J Med; 2016 Nov 24; 375(21):2023-2036. PubMed ID: 27959731
    [Abstract] [Full Text] [Related]

  • 9. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
    Gupta N, Miller A, Gandhi S, Ford LA, Vigil CE, Griffiths EA, Thompson JE, Wetzler M, Wang ES.
    Am J Hematol; 2015 Jul 24; 90(7):639-46. PubMed ID: 25808347
    [Abstract] [Full Text] [Related]

  • 10. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
    Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H.
    Haematologica; 2012 Mar 24; 97(3):393-401. PubMed ID: 22058219
    [Abstract] [Full Text] [Related]

  • 11. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J, Zhao H, Hong M, Zhu H, Zhu Y, Lian Y, Li S, Li J, Qian S.
    BMC Cancer; 2018 Dec 19; 18(1):1269. PubMed ID: 30567513
    [Abstract] [Full Text] [Related]

  • 12. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M, Demolis P, Béhanzin E, Moreau A, Hudson I, Flores B, Stemplewski H, Salmonson T, Gisselbrecht C, Bowen D, Pignatti F.
    Oncologist; 2016 Jun 19; 21(6):692-700. PubMed ID: 27091416
    [Abstract] [Full Text] [Related]

  • 13. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H.
    Lancet Haematol; 2018 Sep 19; 5(9):e411-e421. PubMed ID: 30115541
    [Abstract] [Full Text] [Related]

  • 14. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY.
    Lancet Haematol; 2020 Oct 19; 7(10):e724-e736. PubMed ID: 32896301
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.
    Br J Haematol; 2016 Jan 19; 172(2):238-45. PubMed ID: 26568032
    [Abstract] [Full Text] [Related]

  • 16. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H.
    Cancer; 2015 Jul 15; 121(14):2375-82. PubMed ID: 25809968
    [Abstract] [Full Text] [Related]

  • 17. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
    Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.
    Ann Hematol; 2015 Dec 15; 94(12):2003-13. PubMed ID: 26400023
    [Abstract] [Full Text] [Related]

  • 18. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
    Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH.
    Cancer; 2021 Dec 01; 127(23):4421-4431. PubMed ID: 34424530
    [Abstract] [Full Text] [Related]

  • 19. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM.
    Cancer; 2012 Sep 15; 118(18):4471-7. PubMed ID: 22282348
    [Abstract] [Full Text] [Related]

  • 20. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Ritchie EK, Feldman EJ, Christos PJ, Rohan SD, Lagassa CB, Ippoliti C, Scandura JM, Carlson K, Roboz GJ.
    Leuk Lymphoma; 2013 Sep 15; 54(9):2003-7. PubMed ID: 23270581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.